Promise in the Oncology Drug Pipeline

Business intelligence provider GBI Research found that the oncology drug pipeline is the largest in the pharmaceutical industry, with 6,484 products in active development.
According to Pharmaceutical Processing:

The company’s latest report states that of the pipeline oncology products in development, the majority are in the early stages, with 2,937, equivalent to 45 percent of the total pipeline, at the Preclinical stage, and 1,591, or 25 percent, at the Discovery stage.
Dominic Trewartha, Managing Analyst for GBI Research, says the oncology therapeutic pipeline is highly diverse, containing a broad array of mechanisms of action. This contrasts heavily with the market, which predominantly consists of chemotherapy, hormonal and central nervous system targets.
[…] The analyst also says that a significant characteristic of the oncology treatment pipeline is the overlap between indications, with 24 percent of first-in-class products in development across at least two of the key types of cancer. GBI Research’s report adds that within the oncology segment, cancers of the breast and lung have the highest levels of developmental activity, with a total of 913 and 804 pipeline products, respectively.

Click here to read the full article on Pharmaceutical Processing.